Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus

Ertugliflozin is a selective sodium‐glucose cotransporter 2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). A population pharmacokinetic (popPK) model was developed to characterize the pharmacokinetics (PK) of ertuglif...

Descripción completa

Detalles Bibliográficos
Autores principales: Fediuk, Daryl J., Zhou, Susan, Dawra, Vikas Kumar, Sahasrabudhe, Vaishali, Sweeney, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359437/
https://www.ncbi.nlm.nih.gov/pubmed/33205593
http://dx.doi.org/10.1002/cpdd.885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359437/
https://www.ncbi.nlm.nih.gov/pubmed/33205593
http://dx.doi.org/10.1002/cpdd.885

Ejemplares similares